Amy Kosran6 months ago
Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT
The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.
Source: https://www.medscape.com/viewarticle/998373?src=mbl_msp_android&ref=shareOther commentsSign in to post comments. You don't have an account? Sign up now!